NFKB1 and breast carcinoma: As shown in Figure 9A, azilsartan significantly (p < 0.001) decreased NF-kB protein levels in non-stimulated and 20 ng/mL TNFα-stimulated MCF-7 and MDA-MB-231 breast cancer cells.